van der Aa Maaike A, Schutter Eltjo M J, Looijen-Salamon Monika, Martens Jolise E, Siesling Sabine
Comprehensive Cancer Centre Stedendriehoek Twente, Hoedemakerplein 2, 7511 JP Enschede, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):204-9. doi: 10.1016/j.ejogrb.2007.10.017. Epub 2008 Feb 21.
In The Netherlands, despite a national screening programme since 1996, invasive cervical cancers have been detected in screened and non-screened women. The aim of this study was to determine differences between Pap-smear history, tumour characteristics and survival of patients with a tumour detected by the screening programme (SP) or outside the screening programme (OSP) in the region of the Comprehensive Cancer Centre Stedendriehoek Twente in the period 1992-2001.
In this period, 263 cervical cancer cases in women aged 30-60 were selected from the regional cancer registry. Patient and tumour characteristics, treatment and follow-up data were extracted. Also, detection modality of the tumour and Pap score of the smear which led to the diagnosis ('diagnostic smear') and the 'previous smear' were registered.
Thirty-five percent were SP tumours and 65% were OSP tumours. SP tumours had a lower stage (FIGO I) than OSP tumours: 84% versus 57%. The OSP group exhibited a twofold increase in risk of death (p<0.05) compared to the SP group. Subsequently 61 women (23%) and 46 (17%) women had an abnormal Pap smear (Pap II or higher) 5 and 3 years before the 'diagnostic smear', respectively. Furthermore, 37 women (14%) and 23 women (9%) had a normal smear 5 and 3 years before diagnosis, respectively.
SP tumours have a lower stage and a better prognosis, probably due to the fact that the screening programme detects the slow growing tumours which in general have a better prognosis. Furthermore, detection and treatment of patients with suspicious smears have been suboptimal and attention should therefore be paid to prompt follow-up of suspicious smears.
在荷兰,尽管自1996年起实施了全国性筛查计划,但在接受筛查和未接受筛查的女性中均检测到浸润性宫颈癌。本研究的目的是确定1992年至2001年期间,在特温特综合癌症中心地区,通过筛查计划(SP)或在筛查计划之外(OSP)检测到肿瘤的患者,其巴氏涂片病史、肿瘤特征和生存率之间的差异。
在此期间,从地区癌症登记处选取了263例年龄在30至60岁之间的宫颈癌病例。提取了患者和肿瘤特征、治疗及随访数据。此外,还记录了肿瘤的检测方式以及导致诊断的涂片(“诊断涂片”)和“先前涂片”的巴氏评分。
35%为SP肿瘤,65%为OSP肿瘤。SP肿瘤的分期(国际妇产科联盟I期)低于OSP肿瘤:分别为84%和57%。与SP组相比,OSP组的死亡风险增加了两倍(p<0.05)。随后,分别有61名女性(23%)和46名女性(17%)在“诊断涂片”前5年和3年巴氏涂片异常(巴氏II级或更高)。此外,分别有37名女性(14%)和23名女性(9%)在诊断前5年和3年涂片正常。
SP肿瘤分期较低,预后较好,可能是因为筛查计划检测到生长缓慢的肿瘤,而这类肿瘤总体预后较好。此外,对可疑涂片患者的检测和治疗并不理想,因此应重视对可疑涂片的及时随访。